Related Experiment Video
Updated: May 23, 2026
08:00
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
Published on: May 26, 2021
Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma.
1From Texas Oncology, Fort Worth, Texas.
Journal of the Advanced Practitioner in Oncology
|May 22, 2026
Summary
Quadruplet therapy shows improved progression-free survival and minimal residual disease negativity in frail patients with transplant-ineligible multiple myeloma compared to triplet therapy. Comprehensive frailty assessment guides effective treatment decisions.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Managing newly diagnosed transplant-ineligible multiple myeloma is complex, particularly for frail patients.
- Frailty often leads to exclusion from clinical trials, complicating treatment decisions.
- Quadruplet therapy is being investigated as a potential advancement over triplet therapy for this population.
Purpose of the Study:
- To compare the efficacy of quadruplet versus triplet therapy in transplant-ineligible multiple myeloma patients.
- To evaluate treatment outcomes in frail patient subgroups within the IMROZ and CEPHEUS trials.
- To assess the impact of frailty assessment on treatment decisions and outcomes.
Main Methods:
- Review of data from the IMROZ and CEPHEUS clinical trials.
- Comparison of quadruplet and triplet regimens in intent-to-treat and frailty-defined cohorts.
- Assessment of frailty using the International Myeloma Working Group (IMWG) frailty index and simplified score.
Main Results:
- Patients receiving quadruplet therapy showed longer progression-free survival.
- Higher rates of minimal residual disease negativity were observed with quadruplet therapy.
- Quadruplet therapy demonstrated clinical benefit in selected frail patients with impaired performance status.
Conclusions:
- Quadruplet regimens may offer significant clinical benefits for selected frail patients with transplant-ineligible multiple myeloma.
- Comprehensive frailty assessment and individualized clinical judgment are crucial for treatment decisions.
- Further real-world evidence is needed to confirm tolerability and optimize patient selection for quadruplet therapy.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...